Diagnosis and Treatment of Pancreas Tumours

Alice C. Wei, MD, MSc, FRCSC, FACS
Princess Margaret Cancer Centre
HPB Surgical Oncology and General Surgery
Associate Professor of Surgery, University of Toronto
Lead, Quality and KT, Surgical Oncology, Cancer Care Ontario
BC Surgical Oncology Network, Oct 22 2016
CONFLICT OF INTEREST DECLARATION

I, Alice Wei declare that in the past 3 years:

I have been a member of an Advisory Board or equivalent with the following companies*: Ethicon, Histosonic, Celgene, Sanofi, Takeda, Bayer

I have been a member of the following speakers’ bureau: None

I have done speaking engagements for the following companies*: Sanofi, Celgene

I have received payment or funding from the following companies* (includes gifts, grants, honoraria, and ‘in kind’ compensation): None

I have done consulting work for the following companies*: Cancer Care Ontario

I have held a patent for a product referred to in the program or that is marketed by a commercial organization: None

I or my family hold individual shares in the following companies*: None

I have participated in a clinical trial for the following companies*: None

MANAGING POTENTIAL BIAS

no commercial uses will be discussed

*pharmaceutical, medical device, or communications companies
Learning Objectives

- Learn about the incidence of common pancreatic lesions
- Review the diagnosis and management of pancreas masses
1. Incidental lesions are uncommon and decreasing in frequency
2. Incidental cystic lesions rarely require surgery
3. Mucinous cystic neoplasms require surgery for high risk features
4. Solid pancreatic lesions usually require surgery
5. Mixed duct IPMNs can be followed if < 3 cm
Pancreatic lesions

- pathology is common
  - pancreatitis
    - 5-10/10000
  - pancreatic cancer
    - 4th most common cause of cancer death
    - 4600 cases yearly
- pancreatic cystic lesions
  - detection of lesion increasing
Diagnosis of pancreatic lesions

- many are incidental
  - ~ 50% of pancreatic referrals
  - 48% are solid
  - 25% require resection
- found in work up of
  - GU symptoms (16%)
  - LFT abnormality (13%)
  - screening (7%) or chest pain (6%)
- When symptoms present
  - Pancreatitis, abdominal pain, jaundice
  - Weight loss, fatigue
Approach to pancreatic lesions

- History and physical
  - history of pancreatitis or CBD stones?
  - history of pancreas cancer?
  - Symptoms?

- Imaging essential
  - US → CT → MRI → Eus / Biopsy
Ultrasound

- Safe, inexpensive
  - sensitivity is 88% for solid lesions
  - surveillance of established lesions
  - appropriate screening test

- Disadvantages
  - Quality is operator dependent
  - visualization is limited for:
    - fatty livers
    - obese patients
    - gas overlying the pancreas
CT scan

- Contrast enhanced CT most useful
- Excellent anatomic resolution
  - Defines relationship between lesion and vascular structures
  - Distant/peritoneal disease
- Use pancreas dedicated protocol
  - Arterial/venous phases with coronal/sagittal views
  - Thin slices through the pancreas

Pancreas adenocarcinoma

Pseudocyst
MRI scan

- excellent for CYSTIC lesions
- Good adjunct to CT for indeterminate lesions
- Addition of gadolinium of primovist contrast helpful for indeterminate liver lesions

MRCP
- confirm cystic nature of lesion
- assess biliary and pancreatic ducts
- relationship of lesion to ducts

simple unilocular cyst

IPMN
When to biopsy

- Only when tissue needed to guide Rx
  - i.e. to confirm malignancy
  - Cyst fluid analysis
- EUS preferred when surgery is an option
- Biopsy metastases if present
  - liver biopsy n → easier
  - confirms stage and malignancy
Pancreas lesions

Serous cystic neoplasm

neuroendocrine

adenocarcinoma
Cystic Lesions of Pancreas

- Incidence:
  - Autopsy Series 25%
  - MRI Series 20%

- Evolving knowledge:
  - Histopathology/classifications
  - Clinical significance
  - Management
Cystic Lesions of Pancreas

- **Common**
  - Pseudocyst
  - Serous Cystadenoma
  - Mucinous Cystadenoma
  - IPMN

- **Uncommon**
  - Solid/pseudopapillary epithelioid neoplasm (SPEN)
  - Cystic neuroendocrine
  - Cystic Adenocarcinoma
  - Metastases
  - Simple pancreatic cyst
  - Lymphoepithelial cyst
  - Hydatid cyst
  - Mucinous non-cystic tumor
  - Osteoclast like-giant cell tumor...
Pseudocyst

- Most common cystic lesion (85%)
  - history of pancreatitis common
- majority are asymptomatic
- Symptoms if present
  - Pain, mass effect
  - Bleeding, Infection
- Rx:
  - Asymptomatic $\rightarrow$ observation
  - Symptoms $\rightarrow$ drainage
    - Endoscopic $\rightarrow$ percutaneous $\rightarrow$ surgical
Serous cystic neoplasm

- Median age: 60 years
- 75% female
- Median size: 5 cm
- 65% located in the body and tail

- Usually solitary
- well circumscribed
  - Honeycomb-like structure
  - < 1% malignant transformation

- Rx: Surveillance
**Mucinous cystic neoplasm**

- Thick walled septated cysts
- Median age: 50 years ~75% female
- Usually multilocular
  - NO communication with duct
  - ~90% in body/tail
- 18%-48% malignant transformation
  - Older age, wall calcifications, ↑size, ↑CEA at risk for cancer
- **Rx:** Surgical Excision
  - If cancer →5-year OS ~60%
Intraductal Papillary Mucinous Neoplasm

- **IPMN**
  - ↑ Incidence with age
  - Male > Female
  - Benign or low grade malignancy

- **3 variants**
  - main duct
  - side branch
  - combined/mixed type
Intraductal Papillary Mucinous Neoplasm

- Presentation depends on morphology
  - Asymptomatic $\rightarrow$ side branch
  - Pancreatitis $\rightarrow$ main/combined type
  - ↑malignancy\(^1\) with
    - High risk stigmata
    - Worrisome features
  - if malignant $\rightarrow$ pancreatic adenocarcinoma
- Surgery to PREVENT malignancy

Proportion of malignant IPMN at UHN (2000-2012)

IPMN defined in 2004 by Hruban RH

---

Invasive
Non-invasive

p = 0.008
Wilcoxon test

Year of resection:

Number of resections:
0 2 4 6 8 10 12 14

(Wei et al Manuscript in preparation)
Fukuoka algorithm for IPMN (2012)

Solid pseudopapillary epithelial neoplasm (SPEN)

- Rare, 90% in young woman
- peak incidence 3rd decade
- Asian and African predilection
- majority are benign (85%)
- arise from unknown cell of origin

- Rx: surgical resection
Simple pancreatic cysts

- not very common
  - sporadic → usually isolated
  - familial or syndromic variants
    - PCKD, VHL
- Natural history not clear
- Rx: recommend lifelong surveillance
  - interval? 6-24 months?
Management of pancreatic cystic neoplasms

CT / MRI-MRCP / EUS
Specificity: 90-95%

- Serous Cystadenoma
  - Symptomatic or > 4 cm: consider Surgical Resection
  - Asymptomatic or < 4 cm: Observation

- Mucinous Cystadenoma
  - Surgical Resection

- IPMN
  - Main Duct: Surgical Resection
  - Branch Duct
    - No worrisome features: Observation
    - Worrisome features: Surgical Resection
  - High risk stigmata
    - Worrisome features?: Surgical Resection
Classification of solid pancreatic lesions

Primary Pancreatic Lesions

Benign
- Chronic Pancreatitis
- Auto-immune Pancreatitis
- Pseudo Tumors
- Accessory Spleen
- Hamartomas
- Hyperplasia of the Ampulla of Vater
- Pseudolymphoma
- Granulomatous Inflammation (Sarcoidosis / Tuberculosis)

Potentially Malignant
- Serous / Mucinous Cystadenomas
- IPMN
  1. Main Duct
  2. Side Branch

Malignant
- Exocrine Tumors
- Endocrine Tumors
- Primary
- Secondary

10% of pancreatic masses

90% of pancreatic masses
Pancreatic Carcinoma...coming up next